索卡佐利单抗

• 常用名: 索卡佐利单抗
• 英文名: Socazolimab
• CAS号: 2305043-30-3
• 分子量: N/A
• 密度: N/A
• 沸点: N/A
• 分子式: N/A
• 熔点: N/A
• 闪点: N/A

索卡佐利单抗用途

索唑单抗(ZKAB001)是一种抗PD-L1单克隆抗体。Socazolimab在治疗复发或转移性癌症方面具有持久的安全性和疗效。Socazolimab在小细胞肺癌、食管鳞癌(ESCC)、晚期尿路上皮癌和骨肉瘤中也有潜在应用[1][2][3][4][5]。

索卡佐利单抗名称

• 中文名: 索卡佐利单抗
• 英文名: Socazolimab

索卡佐利单抗生物活性

• 描述: 索唑单抗(ZKAB001)是一种抗PD-L1单克隆抗体。Socazolimab在治疗复发或转移性癌症方面具有持久的安全性和疗效。Socazolimab在小细胞肺癌、食管鳞癌(ESCC)、晚期尿路上皮癌和骨肉瘤中也有潜在应用[1][2][3][4][5]。
• 相关类别:
  研究领域 >> 癌症
  信号通路 >> 免疫及炎症 >> PD-1/PD-L1
• 参考文献:

  [1]. An J, et al. Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study. Clin Cancer Res. 2022 Dec 1;28(23):5098-5106.

  [2]. Lu S, et al. 143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial[J]. Annals of Oncology, 2022, 33: S99.

  [3]. Li Y, et al. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study[J]. Annals of Oncology, 2022, 33: S1101.

  [4]. Duan R, et al. Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma[J]. 2022.

  [5]. Zhou Y, et al. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001. Clin Cancer Res. 2023 Feb 16;29(4):764-774.

索卡佐利单抗物理化学性质

暂时没有任何物化性质资料